Paper Details

  1. Home
  2. Paper Details

Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents.

Author: Abdel-AzizSamira A, AdawyNermin M, AllamAlif A, AyoubBassam A, BasiounyHosam El Din M, BehairyBehairy E, El-ArabyHanaa A, El-GuindiMohamed A, ElhenawyIbrahim A, FouadOla A, KhedrMohamed A, SalemMenan E, SiraAhmad M, SobhyGihan A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

This study assessed the safety and efficacy of a generic sofosbuvir/ledipasvir fixed-dose combination for treating chronic hepatitis C in adolescents and children (9-12 years old).
Paper Details　
Original Abstract of the Article :
Worldwide and national efforts are directed against eradication of HCV. The introduction of direct-acting antivirals (DAAs) has changed dramatically the outcome of HCV treatment. In spite of the Food and Drug Administration approval of the oral drugs sofosbuvir (SOF) and ledipasvir (LED) for the tre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12072-019-09985-w

データ提供：米国国立医学図書館（NLM）

Tackling Hepatitis C in Children: The Promise of Generic Sofosbuvir/Ledipasvir

The global fight against [hepatitis C] has entered a new era with the advent of [direct-acting antivirals (DAAs)]. This study investigates the safety and efficacy of [generic SOF/LED fixed-dose combination 400/90] for treating [chronic hepatitis C (CHC)] in [Egyptian children (9-12 years) and adolescents]. The researchers sought to address the lack of real-world experience with DAAs in this age group, providing valuable insights into the potential of these medications for pediatric patients.

A New Era for Hepatitis C Treatment in Children

This study provides encouraging data on the use of [generic SOF/LED] in [children and adolescents] with [CHC]. The results highlight the safety and efficacy of this combination therapy, offering hope for a more effective and potentially curative treatment option for younger patients.

Combating Hepatitis C: A Global Effort

If you or someone you know is living with [hepatitis C], it is important to consult with a healthcare professional to discuss available treatment options and ensure access to the most effective therapies. The global effort to eradicate this disease is ongoing, with a focus on providing equitable access to care for all.

Dr.Camel's Conclusion

This study is a beacon of hope in the fight against hepatitis C, bringing the benefits of DAAs to a younger generation. It reminds us that even in the vast desert of disease, progress is possible through collaborative efforts and innovative research.

Date :
  1. Date Completed 2020-04-08
  2. Date Revised 2022-08-01
Further Info :

Pubmed ID

31515739

DOI: Digital Object Identifier

10.1007/s12072-019-09985-w

Related Literature

Article Analysis
・Side Effects of ledipasvir and sofosbuvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.